萎缩性胃炎
生物标志物
幽门螺杆菌
医学
胃肠病学
内科学
胃炎
呼吸试验
血清学
快速尿素酶试验
癌症
胃
无色
螺杆菌
胃癌
无症状的
免疫学
抗体
生物
生物化学
作者
Karí Syrjänen,Matti Eskelinen,Ants Peetsalu,Toomas Sillakivi,P. Sipponen,Matti Härkönen,Lea Paloheimo,M Mäki,TAPANI TIUSANEN,Osmo Suovaniemi,F Dimario,Zhu Fan
出处
期刊:Anticancer Research
[International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
日期:2019-03-01
卷期号:39 (3): 1091-1104
被引量:34
标识
DOI:10.21873/anticanres.13218
摘要
Background/Aim: Several clinical conditions seriously hamper the diagnostic accuracy of the commonly used tests for Helicobacter pylori (Hp), 13C-urea breath test (UBT) and stool antigen test (SAT). The present communication is a critical review of the potential limitations of UBT and SAT, and describes the approach on how these can be avoided. Drawbacks of the Hp tests: False-negative results are most often due to low bacterial load in the stomach due to: i) use of proton pump inhibitor medication; ii) use of antibiotics; iii) presence of atrophic gastritis and hypoacid stomach; iv); bleeding peptic ulcer; v) gastric cancer (GC) and vi) mucosal-associated lymphatic tissue lymphoma. The UBT also gives false-positive results when urease-producing bacterial species, other than Hp colonize an acid-free stomach. Importantly, neither UBT nor SAT are capable of diagnosing atrophic gastritis, thus missing the patients at highest risk for GC. GastroPanel® (Biohit Oyj, Finland) circumvents these shortcomings with a serological test consisting of a panel of stomach-specific biomarkers: pepsinogen I, pepsinogen II, gastrin-17 and Hp antibodies. GastroPanel® is a tool for non-invasive examination of i) dyspeptic patients for exclusion or diagnosis of Hp or atrophic gastritis, also disclosing the status of gastric acid output; ii) for screening of asymptomatic individuals at risk of GC; and iii) for comprehensive diagnosis of Hp infection. GastroSoft® application integrates the biomarker profile with the patient9s medical information, accurately classifying the biomarker profiles into eight diagnostic categories. Conclusion: Given that Hp is the single most important risk factor of GC, the non-invasive diagnosis and screening of Hp should be based on more accurate and more comprehensive testing than UBT or SAT alone. The GastroPanel® is such test, being completely devoid of the known serious shortcomings of UBT and SAT.
科研通智能强力驱动
Strongly Powered by AbleSci AI